← All trials
NCT03367559
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 8, 2018
- Primary completion
- Oct 31, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 360
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological ProductsLead sponsor
- Bharat Biotech International LimitedCollaborator
- Vietnam Military Medical UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.